The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...